










BiDil Dosage and Administration

Daily Dosing for BiDil			
	1st Dose	2nd Dose	3rd Dose
Reduced Dose			
Starting Dose			
Maximum Dose (if tolerated)			

- Although titration of BiDil can be rapid (3–5 days), some patients may experience side effects and may take longer to reach their maximum tolerated dose.
- Dosing selection for the elderly should be cautious, usually starting at the low end of the dosing range.
- Dosage may be decreased to as little as one-half BiDil tablet, 3 times a day, if intolerable side effects occur.
- Efforts should be made to uptitrate as soon as side effects subside.
- Treatment of emerging headaches can be managed with acetaminophen.

Indications and Usage

BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. There is little experience in patients with NYHA class IV heart failure. Most patients in the clinical trial supporting effectiveness (A-HeFT) received a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker, and many also received a cardiac glycoside or an aldosterone antagonist.

Please see important safety information on the back.

BiDil[®]
isosorbide dinitrate/hydralazine HCl

Important Safety Information

Contraindications

BiDil is contraindicated in patients who are allergic to organic nitrates.

Warnings

Augmentation of the vasodilatory effects of isosorbide dinitrate by phosphodiesterase inhibitors such as sildenafil, vardenafil, or tadalafil could result in severe hypotension. The time course and dose dependence of this interaction have not been studied. Reasonable supportive care should consist of those measures used to treat a nitrate overdose with elevation of the extremities and central volume expansion.

Adverse Reactions

Adverse events reported in A-HeFT and seen more frequently in the group given BiDil included headache (50% in BiDil patients vs. 21% in placebo patients) and dizziness (32% in BiDil patients vs. 14% in placebo patients).

The full Prescribing Information for BiDil is available at www.bidil.com.

Example of a prescription for recommended start dose



Example of a prescription for maximum dose

